186 related articles for article (PubMed ID: 20689322)
1. Factors associated with recovery of renal function in patients with multiple myeloma who were treated with hemodialysis.
Katagiri D; Hagiwara S; Minami E; Katsuma A; Masumoto S; Hoshino T; Inoue T; Shibata M; Tada M; Nakamura T; Shimbo T; Hinoshita F
Nephron Clin Pract; 2011; 117(1):c28-32. PubMed ID: 20689322
[TBL] [Abstract][Full Text] [Related]
2. Detection of renal impairment as one specific comorbidity factor in multiple myeloma: multicenter study in 198 consecutive patients.
Kleber M; Ihorst G; Deschler B; Jakob C; Liebisch P; Koch B; Sezer O; Engelhardt M
Eur J Haematol; 2009 Dec; 83(6):519-27. PubMed ID: 19614956
[TBL] [Abstract][Full Text] [Related]
3. [Acute and chronic renal failure in patients with myeloma].
Biriukova LS; Volodiaeva EB; Fetisova EV; Pivnik AV; Margolin OV
Ter Arkh; 1999; 71(7):58-64. PubMed ID: 10481869
[TBL] [Abstract][Full Text] [Related]
4. High early mortality rate in elderly patients with multiple myeloma receiving a vincristine-doxorubicin-dexamethasone regimen.
Teng HW; Teng CJ; Wang WS; Chen PM; Chiou TJ; Hsu HC; Liu JH; Yen CC; Hsiao LT; Yang MH; Chao TC; Yang YH; Gau JP
Am J Hematol; 2010 Oct; 85(10):812-5. PubMed ID: 20734459
[TBL] [Abstract][Full Text] [Related]
5. [Withdrawal of maintenance dialysis in a patient with diagnosed multiple myeloma and renal failure as a consequence of effective anti-tumor treatment].
Rosa J; Sydor A; Jurczyszyn A; Zabawa-Hołyś S; Nowak J; Czapkowicz-Gryszkiewicz L; Sułowicz W
Przegl Lek; 2010; 67(7):547-50. PubMed ID: 21387773
[TBL] [Abstract][Full Text] [Related]
6. [Partial recovery of kidney function for an autologous transplant in a patient with chronic kidney disease and multiple myeloma].
de Alarcón Jiménez RM; Roca Meroño S; Alvarez Fernández GM; García Hernández MA; Navarro Parreño MJ; Jimeno Griñó C; Zarco Pedrinaci E; Molina Núñez M
Nefrologia; 2011; 31(2):238-40. PubMed ID: 21461027
[No Abstract] [Full Text] [Related]
7. Haemodialysis using high cut-off dialysers for treating acute renal failure in multiple myeloma.
Martín-Reyes G; Toledo-Rojas R; Torres-de Rueda Á; Sola-Moyano E; Blanca-Martos L; Fuentes-Sánchez L; Martínez-Esteban MD; Díez-de los Ríos MJ; Bailén-García A; González-Molina M; García-González I
Nefrologia; 2012; 32(1):35-43. PubMed ID: 22294003
[TBL] [Abstract][Full Text] [Related]
8. Post-transplant outcomes of induction therapy for myeloma: thalidomide and dexamethasone versus doxorubicin, vincristine, and dexamethasone prior to high-dose melphalan with autologous stem cell support.
Vogl DT; Liu SV; Chong EA; Luger SM; Porter DL; Schuster SJ; Tsai DE; Perl A; Loren AW; Goldstein SC; Nasta SD; Andreadis C; Mangan PA; Hummel K; Siegel DL; Glatstein E; Stadtmauer EA
Am J Hematol; 2007 Dec; 82(12):1071-5. PubMed ID: 17696204
[TBL] [Abstract][Full Text] [Related]
9. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
Palumbo A; Bringhen S; Falco P; Cavallo F; Ambrosini MT; Avonto I; Gay F; Caravita T; Bruno B; Boccadoro M
Cancer; 2007 Aug; 110(4):824-9. PubMed ID: 17594696
[TBL] [Abstract][Full Text] [Related]
10. Early harvest and late transplantation as an effective therapeutic strategy in multiple myeloma.
Gertz MA; Lacy MQ; Inwards DJ; Chen MG; Pineda AA; Gastineau DA; Greipp PR; Lust JA; Tefferi A; Witzig TE; Kyle RA; Litzow MR
Bone Marrow Transplant; 1999 Feb; 23(3):221-6. PubMed ID: 10084252
[TBL] [Abstract][Full Text] [Related]
11. Impact of age on survival after intensive therapy for multiple myeloma: a population-based study by the Nordic Myeloma Study Group.
Lenhoff S; Hjorth M; Westin J; Brinch L; Bäckström B; Carlson K; Christiansen I; Dahl IM; Gimsing P; Hammerström J; Johnsen HE; Juliusson G; Linder O; Mellqvist UH; Nesthus I; Nielsen JL; Tangen JM; Turesson I;
Br J Haematol; 2006 May; 133(4):389-96. PubMed ID: 16643445
[TBL] [Abstract][Full Text] [Related]
12. [Improved prognosis of generalized AL-amyloidosis in a patient with multiple myeloma treated according to the VAD protocol].
Sarkisova IA; Rameev VV; Kozlovskaia LV; Andreeva NE
Ter Arkh; 2003; 75(8):81-2. PubMed ID: 14520860
[No Abstract] [Full Text] [Related]
13. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
14. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.
Ludwig H; Adam Z; Hajek R; Greil R; Tóthová E; Keil F; Autzinger EM; Thaler J; Gisslinger H; Lang A; Egyed M; Womastek I; Zojer N
J Clin Oncol; 2010 Oct; 28(30):4635-41. PubMed ID: 20823423
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.
Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M
Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441
[TBL] [Abstract][Full Text] [Related]
16. Treatment of multiple myeloma: 2009 update.
Prescrire Int; 2009 Dec; 18(104):263-6. PubMed ID: 20025098
[TBL] [Abstract][Full Text] [Related]
17. Multiple myeloma--presenting as acute kidney injury.
Prakash J; Niwas SS; Parekh A; Vohra R; Wani IA; Sharma N; Usha
J Assoc Physicians India; 2009 Jan; 57():23-6. PubMed ID: 19753754
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure.
Tosi P; Zamagni E; Cellini C; Cangini D; Tacchetti P; Tura S; Baccarani M; Cavo M
Eur J Haematol; 2004 Aug; 73(2):98-103. PubMed ID: 15245508
[TBL] [Abstract][Full Text] [Related]
19. [Preliminary report of fludarabine, mitoxantrone and dexamethasone in treating refractory or relapsed multiple myeloma].
Luo SK; Li J; Hong WD; Zhao Y; Tong XZ
Ai Zheng; 2005 Dec; 24(12):1518-21. PubMed ID: 16351805
[TBL] [Abstract][Full Text] [Related]
20. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Kyrtsonis MC; Vassilakopoulos TP; Siakantaris MP; Kokoris SI; Gribabis DA; Dimopoulou MN; Angelopoulou MK; Pangalis GA
Eur J Haematol; 2004 Apr; 72(4):252-8. PubMed ID: 15089762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]